



ESMO VIRTUAL PRECEPTORSHIP

11-12 DECEMBER 2020

Co-Chairs

Viktor Grünwald, DE Jean-Pascal Machiels, BE

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME **HEAD & NECK CANCER**

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

11-12 December 2020

CO-CHAIRS: Viktor Grünwald, Germany **SPEAKERS:** Chia-Jung Busch, Germany

Jean-Pascal Machiels, Belgium

Lisa Licitra, Italy Sandra Nuyts, Belgium Sandra Schmitz, Belgium

LEARNING OBJECTIVES

- To understand epidemiology, aetiology and molecular biology of Head and Neck Squamous Cell Carcinoma (HNSCC)
- To understand multidisciplinary management and treatment of head and neck cancer
- To learn about advances in the treatment and novel targets in head and neck cancer
- To learn about salivary gland cancer

ACCREDITATION

The programme of this event has been accredited with **5 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For the future details please refer to esmo.org

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office **Education Department** Via Ginevra 4 6900 Lugano Switzerland

Email: courses@esmo.org

www.esmo.org



All timings are to be considered CET (Central European Time)

Friday, 11 December 2020

15:00-15:10 10'	Welcome and introduction	Viktor Grünwald, DE Jean-Pascal Machiels, BE
15:10-15:50 40'	SESSION 1 Diagnosis, work-up and biology	Moderator: Jean-Pascal Machiels, BE
10'	Epidemiology and prevention	Viktor Grünwald, DE
20'	Anatomy, diagnosis and work-up + TNM	Sandra Schmitz, BE
10'	Discussion	Faculty/All
15:50-16:05	Break	
16:05-17:15 70'	SESSION 2 - Part 1 Curative treatment of HNSCC	Moderator: Jean-Pascal Machiels, BE
30'	Indications and modalities of radiation or CRT for local and locoregional disease	Sandra Nuyts, BE
30'	Indications and techniques of surgery for the primary treatment of HNSCC	Sandra Schmitz, BE
10'	Discussion	Faculty/All
17:15-18:30 75'	SESSION 2 - Part 2 Treatment of recurrent and/or metastatic HNSCC	Moderator: Viktor Grünwald, DE
15'	Relapsing HNSCC: Salvage locoregional treatment	Sandra Schmitz, BE Sandra Nuyts, BE
20'	Relapsed/metastatic HNSCC: Systemic treatment and immunotherapy	Jean-Pascal Machiels, BE
10'	Discussion	Faculty/All
30'	Participants clinical case discussion (3x10')	Faculty

Saturday, 12 December 2020

15:00-15:20 20'	SESSION 3 Biology of HNSCC	Moderator: Viktor Grünwald, DE
10'	Molecular biology, The Cancer Genome Atlas (TCGA) and biomarkers	Jean-Pascal Machiels, BE
10'	Discussion	Faculty/AII
15:20-15:50 30'	SESSION 4 - Part 1 Salivary gland cancer	Moderator: Viktor Grünwald, DE

15:50-16:30 40'	SESSION 4 - Part 2 Clinical cases	Moderators: Viktor Grünwald, DE Jean-Pascal Machiels, BE
40'	Participants clinical case discussion (4x10')	Faculty
16:30-16:45	Break	
16:45-17:35 50'	SESSION 5 Supportive Therapy	Moderator: Jean-Pascal Machiels, BE
20'	Toxicity Management of IO	Viktor Grünwald, DE
20'	Stomatitis & Locoregional measures (ie. Tracheostoma, PEG)	Chia-Jung Busch, DE
10'	Discussion	Faculty/All
17:35-17:45 10'	Conclusion and farewell	Viktor Grünwald, DE Jean-Pascal Machiels, BE

Note: Each 10-minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion